ZYME:NASDAQ
Zymeworks Inc
US$Â 27.20
arrow_upward
+0.29%(+0.080) Siku 1
US$Â 27.20
0.00% (0.00)
todayKabla ya soko
Imefungwa: 29 Sep, 16:00:00 GMT -4 · USD
search
Alama zote
Siku 1
Siku 5
Mwezi 1
Miezi 6
YTD
Mwaka 1
Miaka 5
ISIZIDI
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya ZYME...
Fungua
US$Â 27.12
Juu
US$Â 28.26
Chini
US$Â 26.76
Mtaji wa soko
1.93B
Wastani wa kiasi cha mauzo
elfu 785.48
Kiasi cha mauzo ya hisa
elfu 3.42
Juu kwa wiki 52
US$Â 31.34
Chini kwa wiki 52
US$Â 16.00
EPS
-US$Â 2.01
Beta
1.19
Hisa za wawekezaji
70.96M
Idadi ya wafanyakazi
231
Fungua
US$Â 27.12
Juu
US$Â 28.26
Chini
US$Â 26.76
Mtaji wa soko
1.93B
Wastani wa kiasi cha mauzo
elfu 785.48
Kiasi cha mauzo ya hisa
elfu 3.42
Juu kwa wiki 52
US$Â 31.34
Chini kwa wiki 52
US$Â 16.00
EPS
-US$Â 2.01
Beta
1.19
Hisa za wawekezaji
70.96M
Idadi ya wafanyakazi
231
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
GuruFocus
·
saa 17 zilizopita
ZYME Maintained by Citigroup -- Price Target Raised to $39.00
MarketBeat
·
saa 20 zilizopita
Zymeworks (NASDAQ:ZYME) Stock Rated "Buy" in New Coverage at TD Cowen
Benzinga
·
siku 1 iliyopita
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Wasifu
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Kuhusu Zymeworks Inc
Afisa Mkuu Mtendaji (CEO)Kenneth Galbraith
Wafanyakazi231
Lilianzishwa2003
Makao makuuVancouver, British Kolumbia, Kanada
Sekta-
Tovutizymeworks.com